MedPath

Medtronic's Inceptiv Spinal Cord Stimulator Receives FDA Approval for Chronic Pain Relief

• Medtronic's Inceptiv, a spinal cord stimulator, has gained FDA approval for managing chronic pain by automatically adjusting stimulation based on biological signals. • The device is implanted and works by sensing signals and blocking pain signals before they reach the brain, offering a potential alternative to traditional pain management. • Dr. Mellisa Murphy and patient Jan Hamilton highlight the device's potential to improve the quality of life for individuals struggling with persistent pain. • Inceptiv represents a significant advancement in neuromodulation therapy, providing personalized and responsive pain relief for chronic pain sufferers.

A new hope has emerged for individuals grappling with chronic pain, as Medtronic's Inceptiv spinal cord stimulator has received FDA approval. This innovative device is designed to provide personalized pain relief by sensing biological signals and automatically adjusting stimulation to block pain signals before they reach the brain.

How Inceptiv Works

Inceptiv is a small, implantable device that delivers targeted electrical pulses to the spinal cord. Unlike traditional spinal cord stimulators that provide constant stimulation, Inceptiv is equipped with advanced sensing technology that monitors the patient's unique biological signals. This allows the device to automatically adjust the level of stimulation in real-time, providing optimal pain relief while minimizing side effects.

Potential Benefits for Chronic Pain Sufferers

Chronic pain can significantly impair a person's ability to perform daily activities, impacting their overall quality of life. Inceptiv offers a potential solution by providing continuous, personalized pain relief. By blocking pain signals before they reach the brain, the device can help individuals regain function and participate more fully in their lives. According to Dr. Mellisa Murphy, this advancement represents a significant step forward in chronic pain management.

Clinical Significance

The FDA approval of Inceptiv marks a significant milestone in the field of neuromodulation. This technology offers a promising alternative to traditional pain management approaches, such as opioids, which can have significant side effects and risks. With its ability to automatically adjust stimulation based on individual needs, Inceptiv has the potential to transform the lives of millions of people living with chronic pain.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Panel Supports Condoliase Injection for Herniated Disc-Related Leg Pain

FDA advisory panel voted 8-4 in favor of condoliase for radicular leg pain due to lumbar disc herniation, highlighting its potential for patients who have not responded to conservative treatments.
The panel emphasized the need for a narrow indication, focusing on patients with confirmed nerve root impingement and failure of at least 6 weeks of conservative therapy.

Pacira Receives FDA Clearance for Iovera System to Treat Chronic Back Pain

Pacira BioSciences has received FDA clearance for its Iovera system with a longer-needle Smart Tip to treat chronic low back pain, offering a drug-free alternative.
The Iovera system uses cryoneurolysis to temporarily halt nerve signals, providing pain relief that can last for months, and has shown benefits in a pilot study.

Corcept Therapeutics Submits New Drug Application for Relacorilant to Treat Cushing's Syndrome

Corcept Therapeutics has submitted a New Drug Application to the FDA for relacorilant, a selective cortisol modulator designed to treat patients with endogenous hypercortisolism (Cushing's syndrome).
The application is supported by positive results from multiple clinical trials, including the pivotal GRACE trial, Phase 3 GRADIENT study, and long-term extension studies, demonstrating improvements in various symptoms with an acceptable safety profile.

FDA Approves Minimally Invasive Sacroiliac Joint Fusion Technique Developed by East Texas Surgeon

Dr. Babajide Ogunseinde received FDA approval for a novel posterior medial to lateral technique to treat sacroiliac joint dysfunction, offering a less invasive option.
The procedure involves a small 2 cm incision and a 3D-printed implant to stabilize and fuse the sacroiliac joints, minimizing soft tissue trauma and blood loss.

TENS Device Shows Promise in Alleviating Long COVID Symptoms

A new study suggests that Transcutaneous Electrical Nerve Stimulation (TENS) may reduce pain and fatigue associated with long COVID.
Participants using the TENS device reported a 26% reduction in pain and an 8% improvement in walking ability compared to the placebo group.

NeurAxis Receives Expanded FDA Clearance for IB-Stim in Abdominal Pain Relief

NeurAxis has secured an expanded FDA 510(k) clearance for its IB-Stim device, a non-implanted nerve stimulator, to broaden its application in functional abdominal pain relief.
The expanded clearance increases the addressable market for IB-Stim by approximately 75% and allows for the use of up to four devices per patient, according to NeurAxis.

FDA Approves RoxyBond, an Abuse-Deterrent Oxycodone for Severe Pain

The FDA has approved RoxyBond (oxycodone hydrochloride), an immediate-release tablet with abuse-deterrent properties, for managing severe pain requiring opioid analgesics.
RoxyBond utilizes SentryBond technology to resist physical and chemical manipulation, reducing the potential for misuse via crushing, dissolving, or injection.

PainWaive: Interactive Game for Neuropathic Pain Enters Clinical Trials

PainWaive, an interactive, home-based EEG neurofeedback system, is set to begin randomized controlled trials in 2025 for neuropathic pain management in spinal cord injury (SCI) patients.
Developed by UNSW Sydney and Neuroscience Research Australia (NeuRA), PainWaive uses a headset and tablet app to help users regulate brain activity associated with neuropathic pain.

Nevro's AI-Powered Spinal Cord Stimulation System, HFX iQ with AdaptivAI, Receives FDA Approval

Nevro's HFX iQ with AdaptivAI, an AI-driven spinal cord stimulation system, has gained FDA approval for chronic pain management.
HFX AdaptivAI leverages AI and patient data to personalize pain relief, optimizing therapy and potentially reducing device charging frequency.

Medtronic Gains FDA Approvals for Percept and Inceptiv Systems

Medtronic's Percept system, a 'pacemaker for the brain,' received FDA approval for managing movement disorders like Parkinson's disease by sending electrical signals to modulate brain rhythms.
The Inceptiv spinal cord stimulator, designed for chronic pain treatment, secured FDA approval with its unique ability to automatically adjust therapy, enhancing pain relief and maintaining stimulation levels.

Reference News

[1]
New FDA-approved device offers hope for chronic pain sufferers
okcfox.com · Sep 7, 2024

A new FDA-approved implantable spinal cord stimulator, Inceptiv™, may offer relief for chronic pain by sensing and adjus...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy